Vir Biotechnology

Analysts weigh in on Vir Biotechnology (VIR), Cardinal Health (CAH), and Waters (WAT). Barclays' Gena Wang maintains a Buy rating on VIR with a $26.00 target. Stephanie Davis also maintains a Buy rating on CAH with a $133.00 target. Luke Sergott maintains a Sell rating on WAT with a $360.00 target.

Blue Trust Inc. increased its stake in Vir Biotechnology by 143.5% in Q3, owning 3,989 shares worth $30,000. Other investors also adjusted their positions, with nVerses Capital LLC and Vontobel Holding Ltd. buying new shares. Vir Biotechnology's stock rose 23.6%, opening at $9.26 with a market cap of $1.27 billion. The company reported a quarterly loss of $1.56 per share, missing estimates, and had a revenue decline of 9.8% YoY. Analysts maintain a 'Moderate Buy' rating with an average target price of $36.80. Director Janet Napolitano sold 12,190 shares at $7.80 each, reducing her ownership.

Needham & Company LLC reiterated a 'buy' rating on Vir Biotechnology (NASDAQ:VIR) with a $19.00 price target, indicating a potential upside of 105.18%. Other analysts also maintain 'buy' ratings, resulting in a 'Moderate Buy' average rating and a consensus target price of $36.80. Vir Biotechnology reported a Q3 loss of $1.56 per share, missing estimates, and revenue of $2.38 million, down 9.8% YoY. Insiders and institutional investors have recently adjusted their holdings in the company.

Vir Biotechnology reported weaker-than-expected quarterly earnings, with a ($1.56) EPS missing estimates by ($0.60) and revenue of $2.38M falling short of $5.54M estimates. The stock opened at $7.14 after closing at $7.49, last trading at $9.03. Analysts maintain 'buy' ratings with varying target prices. Director Janet Napolitano sold 12,190 shares at $7.80 each. Institutional investors increased their holdings, with 65.32% ownership. The company focuses on developing therapeutic products for infectious diseases.

Revenue: US$2.38m (down 9.8% from 3Q 2023). Net loss: US$213.7m (up 31%). US$1.56 loss per share (vs. US$1.22 in 3Q 2023). Revenue missed estimates by 57%, EPS by 63%. Future revenue growth forecast: 53% p.a. (vs. 21% for US Biotechs industry). Shares up 24% in a week. 1 warning sign identified.

Vir Biotechnology Q3 2024 earnings call highlights missed earnings expectations, strategic licensing agreement with Sanofi, progress in hepatitis delta and B programs, and expansion into oncology with T-cell engager assets.

Vir Biotechnology (NASDAQ:VIR) saw unusual options trading activity with a 3,651% increase in call options. Analysts set new price targets, with an average rating of 'Moderate Buy' and a target of $36.80. Insider Janet Napolitano sold shares, reducing her position. Institutional investors increased holdings, with Point72 Asia Singapore Pte. Ltd. boosting its position by 491.7%. Shares opened at $9.26, with a market cap of $1.27 billion. The company reported a revenue of $2.38 million, missing estimates, and has a pipeline targeting infectious diseases.

Vir Biotechnology's Q3 2024 earnings call highlights a licensing deal with Sanofi for three T-cell engager programs, progress in hepatitis trials, and a new CFO emphasizing disciplined financial management. The company reported increased R&D expenses and decreased SG&A expenses, ending the quarter with $1.19 billion in cash and equivalents, and updated its full-year 2024 expense guidance.

Vir Biotechnology's share price has plummeted 76% over the last three years, with revenue dropping 44% annually. Despite not making a profit, the company's weak fundamental performance is reflected in its swift share price decline at an annual compound rate of 21%. Investors should be cautious, as buying a steeply falling share price is often compared to 'catching a falling knife'.